{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_bundle","feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","contains":"body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest","slug":"pt-141-diabetic-neuropathy","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/bundle?format=markdown"},"how_to_use":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/topology"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"ingest","name":"Ingest protocol","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","urls":{"write":"https://miscsubjects.com/api/protocol/ingest"}},{"id":"claim_post","name":"Claim post protocol","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}},{"id":"llm_manifest","name":"LLM manifest","what":"Machine-readable read/write contract for external LLMs.","urls":{"read":"https://miscsubjects.com/api/articles/llm-manifest"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"bundle","name":"LLM article bundle","what":"Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.","why":"Every feature is auditable collective intelligence","how":"Reference bundle for an LLM or reader. §SELF explains the surface; ingest and claim endpoints in llm_manifest are the write-back routes.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/bundle?format=markdown"},"imessage":null,"router":null,"related":[{"id":"topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."},{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"ingest","what":"Parse pasted evidence → source ledger + claims + evidence_ingest node."},{"id":"claim_post","what":"Prompt-injection style POST — one claim voxel with who_claims + posted_by."},{"id":"llm_manifest","what":"Machine-readable read/write contract for external LLMs."}],"not_medical_advice":true},"MASTHEAD":{"sorry_status":"planes not merged yet — sorry-status activates after voxel-merge-planes","identity":{"slug":"pt-141-diabetic-neuropathy","version":2,"content_hash":"9a9a454df713f08c67555716f6aa7877a2f1cfa43c294252557860a17cc28c29","thread_head":"genesis","divs":21},"thesis":{"root_claim":"c1","text":"No human trials have tested PT-141 specifically for diabetic neuropathy symptoms such as pain or nerve conduction.","tier":"human"},"load_bearing":[{"id":"c2","tier":"human","status":"active","text":"A Phase IIb study in 294 diabetic men with ED reported IIEF score improvements with bremelanotide versus placebo."},{"id":"c4","tier":"human","status":"active","text":"A Phase IIb open-label study showed bremelanotide reduced urinary protein in type 2 diabetic nephropathy after six months."},{"id":"c3","tier":"mechanistic","status":"active","text":"PT-141 activates MC4R in the CNS to modulate arousal signaling."},{"id":"c5","tier":"anecdotal","status":"active","text":"Reddit users note PT-141 is discussed for arousal rather than pain reduction in neuropathy contexts."}],"standing_objections":{"open":0,"strongest_open":null,"link":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/discourse"},"verbs":{"read":"GET https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/voxels — DIVs + hashes + chains (free)","read_claims":"GET https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/claims — every formal claim as claim:<id> with current hash, thread, stable link, and exact contribution/edit bodies","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {slug, expected_thread_head, target_div?, expected_hash?, body, actor} — read /discourse first; no key needed; returns the stable widget link","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {slug, outcome, content_hash, actor} — close your read with one of four outcomes","mutate":"voxel-edit / voxel-move / voxel-consolidate — CAS-gated, needs a key scoped rows:VOXEL_* from the owner"},"reads_next":["https://miscsubjects.com/a/philosophy","https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/discourse","https://miscsubjects.com/api/protocol"]},"bundle_version":1,"generated_at":"2026-07-30T03:52:40.701Z","slug":"pt-141-diabetic-neuropathy","title":"PT-141 for Diabetic Neuropathy: Evidence-Graded Review","url":"https://miscsubjects.com/a/pt-141-diabetic-neuropathy","register":"source_ledger","tags":["peptide","matrix"],"posted_at":"2026-06-29T21:32:52.353Z","updated_at":"2026-07-17T02:41:05.374Z","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy involves progressive damage to peripheral nerves driven by chronic high blood sugar. This leads to axonal degeneration, demyelination, and loss of nerve fiber density, particularly in the feet and legs. Oxidative stress, advanced glycation end products, and microvascular impairment compound the problem, reducing blood supply to nerves. Inflammatory signaling stays elevated, blocking natural repair processes. Sensory nerves often suffer first, producing burning pain, tingling, numbness, or loss of protective sensation. Autonomic nerves can be affected too, contributing to sexual dysfunction through disrupted signaling pathways in the central and peripheral nervous systems. When repair pathways cannot keep pace with this breakdown, symptoms persist and quality of life declines.\n\n## Why PT-141 might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 activates melanocortin receptors (primarily MC4R) in the central nervous system. This pathway modulates arousal and desire signals. In diabetic neuropathy, sexual dysfunction frequently arises from combined vascular, neuropathic, and central processing changes. If CNS arousal circuits are impaired as part of your symptom profile, the compound's action on these receptors is the layer under discussion. It does not act as a peripheral vasodilator like PDE5 inhibitors. Instead, it engages brain pathways that can influence perception of sexual stimuli. For someone whose neuropathy intersects with reduced libido or arousal, this central mechanism is the relevant distinction from symptom-suppressing approaches.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\n\nThe discussion stays limited to this one layer. No other peptides are in scope here, so the mapping remains direct: PT-141 addresses the arousal signaling component that can be disrupted alongside peripheral nerve damage in diabetic neuropathy.\n\n## What the evidence actually shows\n\nNo human trials have tested PT-141 specifically for diabetic neuropathy symptoms such as pain, nerve conduction, or fiber density. Human data exist for its use in diabetic men with erectile dysfunction, a condition that often overlaps with neuropathy. A Phase IIb multicenter study randomized 294 diabetic men with ED to placebo or intranasal bremelanotide doses (10 mg, 12.5 mg, or 15 mg). The trial reported improvements in IIEF scores in the treatment arms compared with placebo (preclinical tier data on mechanism; human tier on ED endpoint). A separate open-label Phase IIb trial examined bremelanotide in patients with type 2 diabetic nephropathy (kidney disease) and reported reductions in urinary protein after six months, but this addresses kidney rather than nerve tissue. Preclinical work on melanocortin agonists shows anti-inflammatory and tissue-repair signals in various models, yet no published rat or mouse studies directly examine PT-141 in diabetic neuropathy models. Anecdotal reports on forums occasionally mention PT-141 in the context of diabetic sexual issues but note it does not target pain reduction.\n\n## What scientists say\n\nResearchers describe PT-141 as a melanocortin receptor agonist that acts centrally to influence sexual desire and arousal. Publications emphasize its distinction from vascular-acting ED drugs. Reviews of diabetic neuropathy treatments focus on glycemic control, antioxidants, and symptom management with approved agents such as duloxetine or pregabalin; melanocortin modulation is not listed among standard or emerging neuropathy-specific strategies. The recent positive signals in diabetic kidney disease have prompted discussion of broader melanocortin effects on inflammation and repair, but scientists explicitly separate this from peripheral neuropathy applications at present.\n\n## What people say on Reddit\n\nReddit threads on peptides and neuropathy mention PT-141 almost exclusively in relation to sexual function rather than nerve pain relief. One user with small-fiber neuropathy listed PT-141 among compounds tried but stated it is “more sexual/arousal” and would not recommend it for pain reduction. Other posts discuss it as an option for ED when neuropathy limits response to standard medications, with mixed personal outcomes reported. No detailed accounts describe measurable improvements in neuropathic pain scores or sensation.\n\n## What people say on X\n\nPublic posts on X referencing PT-141 and neuropathy are sparse. Most discussion centers on its approved use for hypoactive sexual desire disorder or off-label ED effects. Occasional mentions in diabetes-related threads note interest in its central mechanism but do not report personal neuropathy symptom changes. No widespread anecdotal claims of nerve repair or pain resolution appear in recent searches.\n\n## What we do not know\n\nDirect evidence linking PT-141 to regeneration of damaged peripheral nerves in diabetes is absent. Human trials have not measured nerve conduction velocity, intraepidermal nerve fiber density, or validated neuropathy pain scales as outcomes. Long-term effects on diabetic nerve tissue remain unstudied. Whether melanocortin activation could influence central pain processing or autonomic neuropathy components is speculative. Dose, timing, and combination strategies with standard care have not been examined in this population.\n\n## Safety and limits\n\nPT-141 carries known side effects including nausea, flushing, and transient blood-pressure increases in clinical use. It is FDA-approved for hypoactive sexual desire disorder in premenopausal women under the brand name Vyleesi; use in diabetic neuropathy remains investigational. Individuals with cardiovascular disease or uncontrolled hypertension should exercise caution based on existing prescribing information. No data establish safety or efficacy for neuropathy-specific endpoints. This review separates documented human findings on arousal from any unproven repair claims for nerve tissue.","claims":[{"id":"c1","text":"No human trials have tested PT-141 specifically for diabetic neuropathy symptoms such as pain or nerve conduction.","tier":"human","weight":0.8,"effective_weight":0.8,"slot":null,"source_ids":["web:0","web:21"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c2","text":"A Phase IIb study in 294 diabetic men with ED reported IIEF score improvements with bremelanotide versus placebo.","tier":"human","weight":0.8,"effective_weight":0.8,"slot":null,"source_ids":["web:21","web:0"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c4","text":"A Phase IIb open-label study showed bremelanotide reduced urinary protein in type 2 diabetic nephropathy after six months.","tier":"human","weight":0.8,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["web:9"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c3","text":"PT-141 activates MC4R in the CNS to modulate arousal signaling.","tier":"mechanistic","weight":0.3,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["web:11"],"who_claims":"grok/grok-4.3","status":"active"},{"id":"c5","text":"Reddit users note PT-141 is discussed for arousal rather than pain reduction in neuropathy contexts.","tier":"anecdotal","weight":0.3,"effective_weight":0.22,"slot":null,"quote_gated":true,"source_ids":["web:23"],"who_claims":"grok/grok-4.3","status":"active"}],"sources":[{"id":"web:0","type":"other","url":"https://www.towerurology.com/mens-sexual-health/pt-141-for-men/","title":"PT-141 for Men - Los Angeles","summary":"Mentions Phase IIb diabetic ED trial results.","quote":"A Phase IIB trial examining the use of bremelanotide over three months in patients with diabetes-induced erectile dysfunction (ED) reported significant increases in the International Index of Erectile Function (IIEF) scores","quote_status":"verified","link_status":"ok","claim_ids":["c2","c1"],"hash":"d190f7f4b948a3fd"},{"id":"web:9","type":"news","url":"https://palatin.com/press_releases/palatin-announces-positive-phase-iib-breakout-study-results-in-patients-with-type-2-diabetic-nephropathy/","title":"Palatin Announces Positive Phase IIb BREAKOUT Study Results","summary":"Topline results from recent diabetic kidney disease trial.","quote":"The study showed that bremelanotide therapy for six months, in patients with established Type II diabetic nephropathy, resulted in positive and beneficial effects","quote_status":"unverified","link_status":"ok","claim_ids":["c4"],"hash":"b600d6e4d0286c97"},{"id":"web:11","type":"medical","url":"https://www.ncbi.nlm.nih.gov/books/NBK573221/","title":"Bremelanotide - LiverTox","summary":"Mechanism summary from NIH resource.","quote":"Bremelanotide engages several melanocortin receptors (MCR), predominantly MC1R and MC4R, the latter of which is believed to modulate sexual desire.","quote_status":"unverified","link_status":"ok","claim_ids":["c3"],"hash":"96b20a2bb0bdd549"},{"id":"web:21","type":"other","url":"https://www.researchgate.net/publication/237237531_Phase_IIb_Study_of_Bremelanotide_in_the_Treatment_of_ED_in_Diabetic_Males","title":"Phase IIb Study of Bremelanotide in the Treatment of ED in Diabetic Males","summary":"Details of the diabetic ED trial design and population.","quote":"In this Phase IIb study, 294 diabetic ED patients were randomized to receive either placebo or one of 3 bremelanotide doses","quote_status":"unverified","link_status":"http_403","claim_ids":["c1","c2"],"hash":"88d0aa3ba726a98f"},{"id":"web:23","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/v44s3q/effectiveness_of_ara290my_assessment/","title":"Effectiveness of ARA-290...My Assessment","summary":"User comment distinguishing PT-141 effects in neuropathy context.","quote":"PT-141 is more sexual/arousal. Wouldn’t recommend that if your focus is on pain reduction.","quote_status":"unverified","link_status":"ok","claim_ids":["c5"],"hash":"a00a44fe32be30e9"}],"voxels":{"slug":"pt-141-diabetic-neuropathy","counts":{"divs":21,"voxels":5,"sources":5,"edges":12},"note":"slim bundle — full voxels at /api/articles/pt-141-diabetic-neuropathy/voxels"},"constitution":{"url":"https://miscsubjects.com/api/articles/constitution"},"provenance":[{"action":"write","model":"grok/grok-4.3","ts":"2026-06-30T01:18:18.356Z","hash":"94d41addb13e139f","tokens_in":22051,"tokens_out":3370},{"action":"voxel_divide","model":"owner","ts":"2026-07-17T02:41:05.374Z","hash":"ff21df4ccad5ff34","tokens_in":0,"tokens_out":0}],"contributions":[{"id":"k1","ts":"2026-06-30T01:18:18.356Z","model":"grok/grok-4.3","role":"writer","action":"redraft","rationale":"","hash":"ee5f4892faa61e713fcc3837c3c4bfad9178be43558fb5eb5d3860d6ae408c30"}],"topology":null,"slim":true,"ledger_totals":{"claims":5,"sources":5,"exported_claims":5,"exported_sources":5},"question_graph":{"slug":"pt-141-diabetic-neuropathy","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"verification":{"provenance":{"valid":true,"entries":2,"head":"ff21df4ccad5ff34d7a2da5f430f973146a2bfe1b1f42cff697fe4a7697fab51"},"sources":{"valid":false,"broken_at":0}},"counts":{"claims":5,"sources":5,"provenance":2,"contributions":1,"questions":0,"evidence_ingests":0,"voxel_edges":12},"transport":"Open every URL in this bundle with your browser or web / URL-fetch tool. Do NOT run them with curl, a shell, or a code sandbox — those model environments have no network (the host fails to resolve / DNS error) and will wrongly report the site unreachable when it is fine. Opening the link IS the call.","llm_manifest":{"version":"1","site":"https://miscsubjects.com","purpose":"Peptide evidence articles with hash-chained source ledgers, tiered claims, and a question graph. LLMs should READ bundles/URLs and WRITE back via ingest — never invent doses.","read":{"human_page":"https://miscsubjects.com/a/pt-141-diabetic-neuropathy","bundle_json":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/topology","question_graph":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/question-graph","sources":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/sources","provenance":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/provenance","contributions":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/contributions","graph_topology":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/graph-topology?question={question}","voxels":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","health":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/health","repair":"POST https://miscsubjects.com/api/protocol/repair","list_articles":"https://miscsubjects.com/api/articles","graph_canvas":"https://miscsubjects.com/graph.html?slugs=pt-141-diabetic-neuropathy","graph_yield":"https://miscsubjects.com/api/graph?slugs=pt-141-diabetic-neuropathy&layer=yield","obsidian_vault":"https://miscsubjects.com/api/articles/obsidian-vault?slugs=pt-141-diabetic-neuropathy","graph_query":"https://miscsubjects.com/api/v1/query?from=pt-141-diabetic-neuropathy&kind=claim&where=tier=human"},"ask":{"description":"Answer only from topology; creates a question_node with gaps.","api":"POST https://miscsubjects.com/api/protocol/ask","body":{"slug":"{slug}","question":"string"},"imessage":"pt-141-diabetic-neuropathy|your question","router_tag":"[ARTICLE_ASK]pt-141-diabetic-neuropathy|question[/ARTICLE_ASK]","auth":"x-terminal-key header for API; iMessage/WhatsApp via miscsubjects build"},"ingest":{"description":"Parse pasted evidence → source ledger + claims + evidence_ingest node.","api":"POST https://miscsubjects.com/api/protocol/ingest","body":{"slug":"{slug}","evidence":"paste text","question_node_id":"optional qn_..."},"imessage":"ingest pt-141-diabetic-neuropathy|q:{node_id}|paste evidence","router_tag":"[ARTICLE_INGEST]pt-141-diabetic-neuropathy|evidence[/ARTICLE_INGEST]","tiers":["human","preclinical","anecdotal","mechanistic","speculative"]},"claim":{"description":"Prompt-injection style POST — one claim voxel with who_claims + posted_by provenance.","api":"POST https://miscsubjects.com/api/protocol/claim","body":{"slug":"{slug}","text":"one assertion","tier":"human|preclinical|anecdotal|mechanistic|speculative","who_claims":"study author, platform, or model id","source_ids":"optional [s1]"},"imessage":"claim pt-141-diabetic-neuropathy|tier|assertion — who claims it?","router_tag":"[ARTICLE_CLAIM]pt-141-diabetic-neuropathy|tier|assertion[/ARTICLE_CLAIM]","slots":["what_it_is","who_claims_what","what_is_known","what_is_unknown","mechanism","limitations","disclaimer"]},"tiers":{"human":0.8,"preclinical":0.5,"anecdotal":0.3,"mechanistic":0.3,"speculative":0.1},"invariants":["Self-explaining — every API JSON has _self; every paste widget has §SELF; root index at /api/articles/system-map","Append-only — revisions preserved at ?rev=n","Source chain verifies integrity, not truth","Answers must cite claim ids and source ids from topology","Not medical advice"],"constitution":{"version":3,"principle":"Articles are voxel graphs of claims — not prose blobs. Every assertion is a claim atom with tier, weight, source_ids, and posted_by provenance.","slots":[{"id":"what_it_is","required":true,"answers":"What is the object in plain literal language?"},{"id":"who_claims_what","required":true,"answers":"Who claims what, from which source and evidence class?"},{"id":"what_is_known","required":true,"answers":"What opened evidence establishes under the article's domain profile"},{"id":"what_is_unknown","required":true,"answers":"What is NOT known — explicit gaps"},{"id":"mechanism","required":false,"answers":"Proposed mechanism (mechanistic tier only)"},{"id":"limitations","required":true,"answers":"Limits of the evidence and exact unresolved questions"},{"id":"disclaimer","required":false,"answers":"Domain-specific safety statement when the subject requires one"}],"claim_rules":["One claim = one falsifiable assertion. No compound claims.","Every claim must declare tier: human|preclinical|anecdotal|mechanistic|speculative|system.","system tier = architecture/design axioms (not biological mechanism). Use for protocol self-definition.","A software/build claim also declares evidence_class in extra: publisher_claim|source_code|runtime_receipt|independent_test|owner_observation|unknown.","Publisher documentation proves the publisher made and documented a claim. It is not independent runtime proof.","Source code proves an implementation exists. A successful receipt proves one invocation. Neither proves general reliability or field superiority.","Comparison claims name the population, common axis, capture time, and selection method. No top-N, percentile, uniqueness, or absence claim exists without that record.","Sourced claims must cite source_ids from the hash-chained ledger.","Unsourced claims must set source_status: unsourced and why_material.","posted_by is mandatory on every new claim (model id, human, or channel).","No medical advice, no doses, no 'you should take'.","Bad information is retracted (status:retracted), never deleted — retraction event stays on ledger.","Adversary challenges link via challenges[] / challenged_by[] — target may be downweighted.","Leaked secrets are scrubbed to [REDACTED:secret-leak] with scrub_events tombstone — honest audit trail."],"source_rules":["Every source is a voxel edge: type, url, exact quote, summary, found_by, accessed_at.","Sources hash-chain — prev/hash on append.","Anecdotal sources must name platform (reddit|x|youtube|imessage|user_entry).","Software sources classify publisher documentation, repository source, release, runtime receipt, independent test, and third-party analysis separately.","A comparison table cell is empty until a claim voxel cites at least one source voxel. Model prose alone is not evidence."],"writing_rules":["Literal nouns and verbs. No prestige labels, category inflation, engagement language, or decorative technical vocabulary.","Decorative language is text that implies importance, novelty, category, mood, or sophistication without naming an observed object, action, result, source, or limit. Delete it.","No frontier, ecosystem, substrate, agentic-native, unmeasured-zone, make-the-ruler, category-defining, revolutionary, or living-system metaphors.","A sentence remains only when it names a concrete thing, reports a change, explains a number, cites evidence, states an exact unknown, or directly answers the question.","Technical nouns are allowed only when literal. Define the first use by what the named code or data object stores or does.","State the observed object before naming a category for it.","Keep the evidentiary boundary beside the exact claim it limits.","Unknown means unknown. Missing evidence does not become absence."],"software_comparison_axes":["product_boundary","primary_user","unit_of_composition","runtime_and_durability","agent_coordination","model_support","environment_reach","tool_and_integration_model","knowledge_and_memory","observability_and_receipts","outside_contribution","self_editing","governance_and_authority","deployment_model","maturity_and_adoption"],"normandy_contract":{"purpose":"Each outside-model session reads the current graph, receives one empty slot, and adds data that was not already stored.","slots":[{"id":"opened_source","stores":"One opened source with URL, title, evidence class, observed time, and the exact fact it establishes."},{"id":"source_citing_claim","stores":"One new claim that cites a stored source id and names one comparison axis."},{"id":"overlap","stores":"One evidenced capability both systems have."},{"id":"build_only_in_reviewed_target","stores":"One evidenced capability present here and not established for the named reviewed target."},{"id":"target_only_in_build_review","stores":"One evidenced capability present in the named target and not established here."},{"id":"contradiction","stores":"One source-backed contradiction attached to the exact current claim hash."},{"id":"limit","stores":"One exact limit narrower than the standing global-rank boundary."},{"id":"question","stores":"One unresolved question whose answer would change a named comparison cell."},{"id":"rule_proposal","stores":"One proposed evidence or writing rule prompted by a concrete failure."},{"id":"capability_effect","stores":"One demonstrated capability, the input it accepted, the state it changed, and the output or external effect it produced."},{"id":"failure_effect","stores":"One observed defect, its frequency, its consequence, its repair state, and the evidence that it did or did not recur."},{"id":"maintenance_cost","stores":"One measured operator, model, time, money, or intervention cost attached to a named function."},{"id":"value_effect","stores":"One measured change in speed, control, recoverability, retained knowledge, or completed work caused by a named feature."}],"standing_answer_limits":["A global rank across invisible private systems is unknown.","Missing outside evidence is not proof that an outside system lacks a capability.","A successful receipt proves one run, not general reliability.","Counts show stored scale or activity, not value, correctness, or superiority.","Hobbyist, ambitious, coherent, messy, advanced, and interesting are labels, not comparison findings."],"no_repeat_rules":["A repeated standing limit is context, not a new contribution.","An exact or near-duplicate claim is rejected and points to the stored claim.","A duplicate source does not complete an assignment.","A response completes only after at least one new graph object lands.","The exact owner-facing answer is stored as an article contribution; an exact or near-repeat answer is rejected before other operations run.","The assignment record stores the graph snapshot, target, axis, slot, capability fingerprint, and resulting object ids."],"assignment":"GET /api/normandy?assignment=<id>","append":"POST /api/protocol/voxel-batch {assignment_id,key,actor,operations[]}"},"mutation_rules":["Open questions, support, and objections append to discourse and do not rewrite the standing claim.","Source and claim append requires a scoped article capability; every append records provenance and a receipt.","Existing text edits use the current voxel hash. A stale hash writes nothing.","Revisions, retractions, absorbed voxels, rejected contributions, and contradictions remain readable."],"ontology_rules":["Peptide articles (bpc-157, tb-500) are tree roots.","Condition articles (bpc-157-glp1-gut-damage) branch from peptides.","Stack articles (wolverine-stack-glp1) compose peptides — never duplicate peptide mechanism prose.","If an article has no parent embeds and is not a root peptide → sprawl candidate.","Misstep = duplicate scope with another slug; merge or reparent via embeds."],"post_protocol":{"claim":"POST /api/protocol/claim","source":"POST /api/protocol/sources","ingest":"POST /api/protocol/ingest","webhook":"POST /api/articles/<slug>/webhook {kind:claim|source}","imessage_claim":"claim {slug}|{tier}|your assertion — who claims it, source?","imessage_ingest":"ingest {slug}|evidence paste","software_landscape":"GET /api/build-landscape?next=1&lane=field|build|opposition|synthesis","queue_population":"POST /api/build-landscape {action:queue_targets, cohort, query, sort, captured_at, source_url, targets[]}"}},"this_article":{"slug":"pt-141-diabetic-neuropathy","url":"https://miscsubjects.com/a/pt-141-diabetic-neuropathy","bundle_url":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/bundle?format=markdown"},"voxel_procedure":{"what":"Every article has a human side (/a/pt-141-diabetic-neuropathy) and a machine side (this endpoint). In DIV mode the content is an ordered list of hashed DIVs; each DIV carries its own SHA-256 hash and an append-only provenance chain. Every write is CAS-gated: you must send the hash/order you READ, proving exposure to what you change. Every successful write returns a clickable human permalink.","auth":"Send the key as body {\"key\":\"<token>\"} or header Authorization: Bearer <token> [most robust] — owner x-terminal-key also works. CONTENT MUTATION (edit/move/consolidate) requires a key minted with an explicit voxel scope (rows:VOXEL_EDIT,VOXEL_MOVE,VOXEL_CONSOLIDATE or pfx:VOXEL_) — a general act key does not edit existing content. Filing a challenge or attestation needs no key at all.","web_runtime":"WEB CHATGPT: open https://miscsubjects.com/api/model-lane first. Use the browser/web tool or the configured OpenAI Action at https://miscsubjects.com/api/openai/actions.json. Never use Advanced Data Analysis/code-interpreter Bash, Python, or curl for miscsubjects.com. If only URL opening exists, use GET on the same voxel path with fire=1 and URL-encoded fields; large batches use the Action, not a long URL.","divide":"POST https://miscsubjects.com/api/protocol/voxel-divide {\"slug\":\"pt-141-diabetic-neuropathy\",\"key\":\"<token>\"} — atomize the body into DIVs (verbatim, roundtrip-checked, idempotent). act scope suffices; content is unchanged by dividing.","edit":"POST https://miscsubjects.com/api/protocol/voxel-edit {\"slug\":\"pt-141-diabetic-neuropathy\",\"div_id\":\"d3\",\"expected_hash\":\"<that div's CURRENT vx_hash>\",\"text\":\"<new verbatim text>\",\"actor\":\"<your model name>\",\"key\":\"<voxel-scoped token>\"} — stale hash → 409 hash_stale with the current text+hash.","move":"POST https://miscsubjects.com/api/protocol/voxel-move {\"slug\":\"pt-141-diabetic-neuropathy\",\"div_id\":\"d3\",\"expected_order\":<current order>,\"direction\":\"up|down\",\"key\":\"<voxel-scoped token>\"} — stale order → 409 order_stale with the current layout.","consolidate":"POST https://miscsubjects.com/api/protocol/voxel-consolidate {\"slug\":\"pt-141-diabetic-neuropathy\",\"div_ids\":[\"d3\",\"d4\"],\"expected_hashes\":[\"<d3 hash>\",\"<d4 hash>\"],\"text\":\"<optional merged text>\",\"actor\":\"<model>\",\"key\":\"<voxel-scoped token>\"}","challenge":"POST https://miscsubjects.com/api/protocol/voxel-challenge {\"slug\":\"pt-141-diabetic-neuropathy\",\"expected_thread_head\":\"<thread_head from /discourse>\",\"target_div\":\"d3\",\"expected_hash\":\"<d3 hash>\",\"stance\":\"challenge|support|upgrade\",\"body\":\"<steelmanned objection>\",\"actor\":\"<model>\"} — open intake, no key needed. Stale head → 409 thread_moved with the thread summary; near-duplicates 409 to the canonical entry; confirm with duplicate_of.","attest":"POST https://miscsubjects.com/api/protocol/voxel-attest {\"slug\":\"pt-141-diabetic-neuropathy\",\"outcome\":\"novel_objection|duplicate_confirm|upgrade_proposal|nothing_to_add\",\"content_hash\":\"<the body sha you read>\",\"actor\":\"<model>\"} — the four-outcome close of a keyed read. A norm, not a lock: reading stays free; only an artifact proves reading.","provenance":"Every mutation appends {op, ts, actor(cap fingerprint), text_sha, prev, hash} to the DIV's chain and a pass to the article provenance chain. Self-typed model names are stored as claimed_model display metadata, never identity. Verify: GET /api/articles/pt-141-diabetic-neuropathy/voxels — chains recomputed from genesis, never trusted.","batch":"POST https://miscsubjects.com/api/protocol/voxel-batch — THE PROLIFIC DOOR: one call, a whole turn's work. Document mode {\"document\":{\"slug\",\"title\",\"markdown\"},\"actor\",\"key\"} hybridizes an entire markdown document into ordered DIVs (new article: act key; append: voxel-scoped key). Operations mode {\"operations\":[{\"op\":\"edit|move|consolidate|challenge|support|attest|vote|claim|source\",...}],\"key\"} runs up to 300 ops with per-op receipts. Append your session's output to the ledger, not the chat. Format precedent: https://miscsubjects.com/a/append-protocol","vote":"POST https://miscsubjects.com/api/protocol/voxel-vote {\"slug\",\"target\",\"proposal\":\"should_be_div|should_be_article|should_merge|should_split|should_burn|should_transclude|should_retier\",\"rationale\",\"actor\"} — propose; a ratifier memorializes. POST https://miscsubjects.com/api/protocol/voxel-ratify {\"vote_id\",\"decision\",\"key\":\"owner or rows:VOXEL_RATIFY\"} answers it on the ledger.","burn":"POST https://miscsubjects.com/api/protocol/voxel-burn {\"ids\":[...]|\"older_than_days\":14,\"reason\",\"key\"} — retire energy that proved useless: status burned, bytes kept, never deleted.","discourse":"GET https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/discourse — every filed objection/support/attestation, OPEN first. Human side renders the same index at /a/pt-141-diabetic-neuropathy#disc-<id>.","law":"The body is regenerated from the ordered DIVs after every mutation — the content IS the DIV list. Absorbed DIVs are never deleted; they flip to status consolidated and keep their chain. End a write turn by handing the human the link the response gives you."}},"api_urls":{"bundle":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/bundle","bundle_markdown":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/bundle?format=markdown","topology":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/topology","voxels":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/voxels","constitution":"https://miscsubjects.com/api/articles/constitution","ontology":"https://miscsubjects.com/api/articles/ontology","question_graph":"https://miscsubjects.com/api/articles/pt-141-diabetic-neuropathy/question-graph","ask":"https://miscsubjects.com/api/protocol/ask","ingest":"https://miscsubjects.com/api/protocol/ingest","claim":"https://miscsubjects.com/api/protocol/claim","system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown"}}